Brought to you by 
Merck KGAA, Pfizer, and Syndax enter ovarian cancer trial collaboration
11 Oct 2021
Executive Summary
Merck KGAA, Pfizer Inc., and Syndax Pharmaceuticals Inc. entered into an agreement to explore a combination of the anticancer therapies avelumab and entinostat for patients with heavily pre-treated recurrent ovarian cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck KGAA, Pfizer, and Syndax enter ovarian cancer trial collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice